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ABSTRACT 
 
BACKGROUND 
Acute pancreatitis (AP) is the most terrible of all the calamities that 
occur in connection with the abdominal viscera.  The suddenness of its 
onset, the illimitable agony which accompanies it, and the mortality 
attendant upon it, all render it the most formidable of catastrophies. 
Acute pancreatitis is a common emergency disease with widely 
varying severity.  Its wide clinical variations make the diagnosis complex. 
Mostly, only mild cases and conservative treatment results in rapid 
recovery. Severe disease  constitutes 15–20% of all cases with frequent 
involvement of regional tissues and remote  organ systems as two phase 
systemic disease. In the first phase extensive pancreatic inflammation 
and/or necrosis  are followed by a systemic inflammatory response 
syndrome (SIRS) that may lead to multiple organ dysfunction syndrome 
(MODS) within the first week. About 50% of deaths occur during the 
first week of the attack, mostly from MODS. Unless the first phase is 
treated, the second phase ensues after the second week of onset and 
includes the development of infected pancreatic necrosis or fluid 
collection with possible progression to overt sepsis, MODS and death. 
Early identification of acute pancreatitis and especially detection of 
severe form of the disease is very important. 
 
 
 
 
Currently, the diagnosis of acute pancreatitis is based on 
measurements of serum amylase and/or lipase activity, which are 
considered unsatisfactory due to their low level of accuracy.   There are a 
number of well known measurements for evaluating the prognosis of 
acute pancreatitis, such as the RANSON, GLASCOW, BISAP and Acute 
Physiology and Chronic Health Evaluation (APACHE II). All of these 
require measurement of many clinically-based parameters and are very 
complicated and time consuming. In this study, usefulness of C-reactive 
protein to assess and monitor  the severity of acute pancreatitis was 
evaluated. 
OBJECTIVES 
The primary objective is study on C-reactive protein for assessing and 
monitoring the severity of acute pancreatitis. 
METHOD 
This is a prospective study, where 75 patients admitted to our 
hospital with acute pancreatitis, who met with the inclusion and exclusion 
criteria, were subjected to clinical examination and relevant 
investigations such as serum amylase, serum lipase, USG abdomen, serial 
monitoring of C-reactive protein. The results are evaluated and analyzed 
by comparing with serial monitoring of alpha 1 antitrypsin. White cell 
 
 
 
 
count, erythrocyte sedimentation rate, temperature were used as reference 
data. 
RESULTS 
In our study of 75 patients of acute pancreatitis, 39 patients were 
found to have mild disease and 36 patients were found to have severe 
acute pancreatitis according to Atlanta criteria 2012. Etiologies of the 
disease were alcoholic, biliary and idiopathic. 
Samples for CRP, Alpha 1 Antitrypsin, WBC, and ESR were 
collected on day1 of admission and on days 3, 5, 7, 9, 11 after admission. 
Temperature, ESR, Alpha1Antitrypsin values didn’t discriminate acute 
pancreatitis as mild and severe disease.  Although those values were high 
in severe acute pancreatitis, mean 95% confidence limits of mild and 
severe attacks were overlapped throughout the study. 
On day 1 of admission, difference in WBC count between mild and 
severe disease, helps to discriminate between the two. As the disease 
progressed, CRP values reaches maximum in the end of first week, in 
severe acute pancreatitis and it takes more time to fall towards normal 
value.  Hence CRP helped to differentiated between mild and severe 
acute pancreatitis better than WBC and Alpha 1 antitrypsin value.  High 
level of CRP (>100mg /l) at first week suggests that patients who have 
 
 
 
 
the disease requires 2 or more weeks to recover and there is risk of 
developing pancreatic collection.  
Increased values of CRP reflect severe local inflammation in mild 
disease with benign clinical course. 
Hence, CRP is a sensitive indicator of continuing inflammation and 
it may be of  better value in selecting the cases who are more prone for 
developing high risk complications. 
CONCLUSION 
Temperature, ESR, Alpha1Antitrypsin values didn’t discriminate 
acute  pancreatitis as  mild or severe disease.  Although those values 
found high in severe acute pancreatitis, mean 95% confidence limits of 
mild and severe attacks were overlapped throughout the study. 
Of the inflammatory markers studied, CRP was able to differentiate 
acute pancreatitis into mild and severe forms  with greatest precision.   
KEY WORDS  
C - reactive protein,  Alpha 1 Antitrypsin, Erythrocyte 
sedimentation rate, Acute pancreatitis, Severity. 
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INTRODUCTION 
 
Acute pancreatitis (AP) is a common emergency disease with 
widely varying severity.  Its wide clinical variations make the diagnosis 
complex. Most of them are mild cases and early medical intervention 
enhances rapid recovery. Severe Acute pancreatitis accounts about 20% 
of all cases. It is a two phasic systemic disease involving both local as 
well other system.  The first phase is characterized by severe pancreatic 
inflammation with or without necrosis. This may leads to systemic 
inflammatory response syndrome (SIRS) which may cause multiple organ 
dysfunction syndrome (MODS) and 50% of deaths in the first week of the 
disease course. Unless the first phase is treated, the second phase starts 
with the development of fluid collection or necrosis which may leads 
sepsis and death. 
Early identification of the disease and prediction of severity of the 
acute pancreatitis is very important. There are different scoring systems 
available for the early assessment of AP. Most widely used scoring 
systems are RANSON, BISAP and APACHE. They are cumbersome and 
difficult to use in clinical practices because of their multifactorial nature. 
Unifactorial prognostic indices such as C - reactive protein (CRP), 
serum amylase, serum lipase and alpha-1 antitrypsin are easy to obtain in 
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normal practice. Several research people evaluated CRP as predictor for 
severity of acute pancreatitis and found CRP differentiates mild and 
severe forms of the acute pancreatitis with greatest precision and is highly 
sensitive in detecting necrotic forms of AP. 
In this study, we evaluated C Reactive Protein (CRP) as a marker 
for assessing and monitoring  the severity of acute pancreatitis and the 
collected data were compared with the values given by the white cell 
count, erythrocyte sedimentation rate, temperature and by alpha 1 
antitrypsin.  We analyzed the data and found that CRP value was high 
(100 mg/dl) at the end of the first week of acute pancreatitis and serial 
high CRP levels in serum is a definite indicator of severity of the acute 
pancreatitis than white cell count, erythrocyte sedimentation rate, 
temperature and alpha 1 antitrypsin. 
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REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS 
 Herophilus  (335–280 BC) was the first person identified the 
pancreas. A few hundred years after, Rufus named the pancreas. 
 In 1642-Johann George Wirsung, a Physician in Germany, 
discovered Main pancreatic duct  ( Wirsung’s duct ). 
 In 1724, Giovanni Domenico Santorini dissected accessory 
pancreatic duct  ( Santorini’s duct ). 
 In 1833, Anselme payen isolated amylase, a enzyme present in 
exocrine pancreas. 
 In 1893, Gustav-Edouard Laguesse given the name Islets of 
Langerhans as an honour of Paul Langerhans. 
 In1922, Frederick Banting and John Macleod discovered insulin 
and win the Nobel prize in 1923.Banting shared his part of the 
prize money with a younger coworker Charles Best. 
 In 1953, Staub Sinn and Behrens purified Glucagon, otherwise 
known as “hyperglycemic glycogenolytic factor”. 
 1965, Axelssor and Laurell investigated the allelic variants of 
Alpha 1 Antitrypsin causing disease. 
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EMBRYOLOGY OF PANCREAS 
Septum transversum produces two pancreatic buds at the junction 
of foregut and midgut at fifth weeks of gestation from endodermal lining 
of duodenum distal to future stomach. The larger dorsal bud grows 
rapidly than the smaller ventral bud. The ventral bud rotates towards the 
dorsal bud as it is carried by common bile duct. Inferior part of head of 
the pancreas and uncinate process develops from the ventral bud. Dorsal 
bud gives rise to head, whole of neck, body and tail of this organ. The 
major pancreatic duct  forms from ventral bud and terminal part of dorsal 
bud, whereas the accessory pancreatic duct forms from proximal part of 
dorsal bud. 
 
Fig. 1. Embryology of Pancreas. 
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DEVELOPMENTAL ANOMALIES OF THE PANCREAS 
 
1. Pancreas  divisum  is one of the congenital defect in which  there 
is no fusion of ventral and dorsal pancreatic ducts. There are three 
variants of pancreatic divisum. 
a. Type 1 ( Classical divisum ) where there is total failure of 
fusion. 
b. Type 2 where dorsal drainage is dominant in the absence of 
the duct of Wirsung. 
c. Type 3 ( Incomplete divisum ) where a small 
communicating branch is present 
 This is associated with recurrent acute pancreatitis because of              
inadequate drainage of pancreatic secretions via the minor papilla. 
2. As a results of failure of the ventral bud to rotate with the 
duodenum producing an annular pancreas, encircling the second 
part of the duodenum. 
Annular pancreas may be the cause of duodenal obstruction in 
neonatal period. In adults, it is asymptomatic and discovered 
incidentally. It may be the cause of gastric outlet obstruction, 
acute or chronic pancreatitis or peptic ulcer bleeding.  Ectopic 
pancreas is found mostly at gastric antral sub mucosa, proximal 
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part of the duodenum or the jejunum. This is usually 
asymptomatic or symptomatic when complications such as 
ulceration, bleeding develops. 
3. Absence of the ventral or dorsal pancreatic buds results in 
Pancreatic agenesis. 
4. Accessory pancreatic tissue will  be present in  duodenal wall, 
jejunum ,ileum  or  Meckel's diverticulum. 
5. Inversion of pancreatic ducts: In this condition, the accessory 
duct is larger than the main duct, and the main drainage of the 
pancreas is through the minor duodenal papilla 
 
 
               
 
                                 Fig. 2. Pancreas divisum 
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ANATOMY 
 
The pancreas (pan = all; kreas = flesh in Latin), originally means 
sweetbread, is both exocrine and endocrine soft, lobulated retroperitoneal 
organ located in  left  upper  part of the abdomen obliquely behind  
stomach at the level of first and second lumbar vertebrae extending from 
the C-loop of the duodenum to the splenic hilum (Fig 3).The pancreas is 
about 15-20 cm long, 2.5-3.8 cm broad and 1.2-1.8 cm thick and weighs 
about 75 to 100g.  
                       
 
Fig. 3.Location of Pancreas. 
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Anatomically,  the pancreas is divided into four parts 
1.Head 
2.Neck 
3.Body and 
4.Tail 
1.Head of the pancreas 
Head is situated within the duodenal curvature. Head has two 
surfaces (anterior and posterior), three borders, (superior, inferior and 
right lateral),one process, named the uncinate process, which projects to 
the left arising from lower part of the head. 
The anterior surface relations are gastro duodenal artery, transverse 
colon and jejunum from above downwards. The relations of posterior 
surface are inferior vena cava, renal veins, right crus of the diaphragm, 
and bile duct. Superior border overlaps first part of pancreaticoduodenal 
artery. The inferior border is related to inferior pancreaticoduodenal 
artery and to third part of duodenum. Right lateral border related to 
terminal bile duct, duodenum at the second part, and anastomosis 
between the two pancreaticoduodenal arteries. 
Uncinate process is related to the superior mesenteric vessels 
anteriorly, and to the aorta posteriorly. 
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2.Neck 
The neck measures of length 2.5 cm and lies between head and 
body. It is directed upwards and forwards at first, and then upwards and 
to the left, with two surfaces, anterior and posterior. The relations of 
anterior surface are the pylorus and the peritoneum covering the posterior 
wall of the lesser sac.  The gastroduodenal and superior 
pancreaticoduodenal arteries lie at its junction with the head. The 
relations of posterior surface are termination of the superior mesenteric 
vein and the beginning of the portal vein.  
 
 
Fig 4.Parts and relations of Pancreas. 
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3.Body 
The largest part of the pancreas is the body which is elongated and 
located at the level of transpyloric plane which inclines upward and 
backward slightly towards the left. A projection called the tuber 
omentale is a part of the body projects upwards beyond the lesser 
curvature of the stomach, and is related to the lesser omentum across the 
lesser sac.  
It has three surfaces, anterior, posterior and inferior and three 
borders anterior, superior and inferior. The anterior surface is related to 
the stomach and to the lesser sac with peritoneal covering.  
The posterior surface is devoid of peritoneum, and is related to the 
aorta with the origin of the superior mesenteric artery, left crus of the 
diaphragm, left suprarenal gland, left kidney, left renal vessels and 
splenic vein. The inferior surface is related to the duodenojejunal flexure, 
the left colic flexure, and the coils of jejunum and is covered by 
peritoneum.  The root of the transverse mesocolon attached to the anterior 
border. The superior border is related to the hepatic artery to the right and 
the splenic artery to the left, coeliac trunk over the tuber omentale. The 
inferior border is related to the superior mesenteric vessels at its right 
side. 
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4. Tail of the Pancreas lies in the lienorenal ligament and ends by 
contacting with the gastric surface of the spleen. 
Ducts of  Pancreas 
The secretions of exocrine pancreas drains into two ducts. 
1. The main pancreatic duct of Wirsung with diameter of about 2 to 
3mm begins at the tail receives numerous small tributaries at right angles 
to its long axis formig‘herring bone pattern’. It runs through the body and 
the neck, opens at the ampulla of Vater after joining with the common 
bile duct, which opens on the summit of the major duodenal papilla, on 
the medial aspect of the duodenum at the second part 8 to 10 cms distal to 
the pylorus. 
2. The accessory duct ( Santorini duct ) begin in the lower part of the 
head, and open into the duodenum at the minor duodenal  papilla which is 
situated 6 to 8 cm distal to the pylorus ventral to that of the main duct. 
The sphincter of Oddi is the muscle fibers around the ampulla. 
 
Fig. 5. A. Anatomy of the papilla; B. Sphincter; C.Endoscopic view. 
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BLOOD SUPPLY 
The following  are the arteries supplying the pancreas : 
(1)Pancreatic branches of the splenic artery, 
(2) Superior pancreaticoduodenal artery, and 
(3)Inferior pancreaticoduodenal artery (Fig.6) 
As the duodenum and the pancreas develops at the junction of the foregut 
and midgut, branches of both the coeliac and superior mesenteric arteries 
supplies it. 
 Venous drainage is by splenic vein, superior mesenteric vein and portal 
veins. 
 
Fig 6.Blood supply of Pancreas. 
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LYMPHATIC DRAINAGE 
Lymphatics follow the arteries and empties into the following groups of 
lymph nodes 
1. Pancreaticosplenic, 
2. Coeliac and 
3. Superior mesenteric lymph nodes  
NERVE SUPPLY 
The vagus nerve which is parasympathetic and sympathetic splanchnic 
nerves supply the pancreas through the plexuses around its arteries. 
Parasympathetic nerve regulates pancreatic secretion. Sympathetic nerves 
are vasomotor. 
HISTOLOGY 
The pancreas is divided into lobules by connective tissue septae which is 
the invagination of capsule. 
The exocrine portion of pancreas consists of acini and ducts. Acinus 
(Latin word meaning berry in a cluster ) are the pear shaped cells lined by 
pyramidal cells with basal round nuclei, containing zymogen granules. 
These cells synthesis and secrete the digestive enzymes rich in alkaline 
bicarbonate ions.   Pancreatic exocrine secretion from acini flow through 
ducts into the duodenum and are classified into four types. 
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1. Intercalated ducts have flattened cuboidal epithelium that extends 
up into the lumen of acinus to form centroacinar cells 
2. Intralobular ducts have classical cuboidal epithelium and are seen 
within lobules. Secretions from intercalated ducts drain into it. 
3. Interlobular ducts are found between lobules. The smaller ducts 
have cuboidal epithelium and the larger ducts have columnar 
epithelium. They receive secretion from intraocular ducts.  
4. Main pancreatic duct receive secretion from interlobular ducts 
and penetrates through the wall of the duodenum.  
 
 
Fig.7.Histology of Pancreas. 
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Endocrine  part consist of  specialized clumps of secretory cells called 
Islets of Langerhans among acini, supported by reticulin fibres and 
delicate capsule and contains three major cell types. 
Alpha cells with subtype A1 and A2. These are granular and acidophilic 
and form about 20% of the cell population. Al cells belong to 
enterochromaffin group and secrete pancreatic gastrin and serotonin. A2 
cells secrete glucagon. 
Beta cells which are granular and basophilic, forming about 80% of the 
cell population and produce insulin. 
Delta cells secrete somatostatin. Islets are supplied by arterioles with 
branching fenestrated capillaries, into which hormones are secreted, 
drained by venules which pass into interlobular vein.  
 
         
 
Fig.8.Exocrine and Endocrine Parts of Pancreas. 
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FUNCTIONS 
1.Exocrine pancreas: 
The pancreas produces 500 to 800 ml of colorless, odorless 
secretion per day. Secretion contains juice from acinar cell and duct cell 
mainly alkaline. Amylase, proteases, and lipases are the enzymes secreted 
by the acinar cell which helps in digestion of  carbohydrates, protein and 
fat. 
Amylase is the active form of the enzyme secreted in the pancreas, and it 
digest starch and glycogen to glucose.  Lipase breaks down fat into fatty 
acids and glycerol.   
The function of acinar cells is to synthesis and secrete the inactive 
digestive enzyme precursors (trypsinogen, proelastases, prophospholipase 
A2) into the duodenum.  
Endoplasmic reticulum in the cell, synthesis zymogens and packed 
into secretory granules. Upon stimulation of acinar cells, granules  
discharge the contents into lumen of acinus by exocytosis and drains  into  
duodenum via the ducts.  In the duodenum, enterokinase catalyse the 
conversion of inactive trypsinogen to active trypsin. 
  Trypsin activates the other proteolytic enzymes, including its 
proenzyme trypsinogen. The acinar cells also secretes inhibitors which 
prevents activation of trypsinogen within the pancreas. A failure to 
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express a normal trypsinogen inhibitor, pancreatic secretory trypsin 
inhibitor (PSTI),also known as serine protease inhibitor Kazal type 1 
(SPINK1),is a cause of familial pancreatitis. 
Acinus is a spherical unit which contains 40 acinar cells .Chloride 
secretion varies inversely with bicarbonate secretion such that the sum 
of  these two remains constant. Bicarbonate secretion, buffers  acidic 
fluid which drains from the stomach into the duodenum . CCK potentiates 
secretin-stimulated bicarbonate secretion.  
 
 
Fig.9 Cellular structure of pancreas 
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Table.1.PANCREATIC ENZYMES 
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2.Endocrine Pancreas: 
The adult pancreas contains 1 million islets of Langerhans. Most islets 
contain 3000 to 4000 cells of five major types. Their properties are shown 
in the table (Table . 2) 
Table 2. PANCREATIC ISLET PEPTIDE PRODUCTS 
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PANCREATITIS 
Pancreatitis is the acute inflammation of the pancreas. 
Pancreatic  damage occurs when the digestive enzymes are activated 
before they are released into the small intestine and  begin attacking the 
pancreas.  Pancreatitis is divided into  1.Acute pancreatitis 
                                                   2.Chronic pancreatitis 
ACUTE PANCREATITIS (AP) 
Sudden inflammation of the normally existing pancreas is called acute 
pancreatitis. 
Acute pancreatitis may be first attack or relapsing attack with normal 
gland in between. 
CLASSIFICATION OF ACUTE PANCREATITIS 
ATLANTA CRITERIA (1992) 
 Mild acute pancreatitis (80% cases) 
Acute interstitial /edematous pancreatitis 
- Acute absence of organ failure 
- Absence of local complications 
 Severe acute pancreatitis (20%) 
Acute  haemorrhagic necrotising(fulminant) pancreatitis 
- Local complication +/- 
              - Organ failure defined as 
 
 
 
 
21 
 
• SBP <  90 mmHg 
• PaO2 ≤ 60 mmHg 
• GI bleed ≥ 500ml/24hours 
• Creatinine  ≥ 2 mg/dl after rehydration 
              -Ranson  score ≥ 3 or APACHE ≥ 8  
REVISED ATLANTA CRITERIA (2012) 
Mild acute pancreatitis 
- Absence of organ failure.  
- Absence of local complications. 
Moderately severe acute pancreatitis 
- Local complications +/- 
- Transient organ failure (< 48 hours) 
Severe acute pancreatitis 
-Persistent organ failure (>48 hours) and /or death. 
Acute pancreatitis is usually a mild disease with minimal organ 
dysfunction. However,15-20% of all cases demonstrate severe acute 
pancreatitis 
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Fig.10.Acute pancreatitis 
CHRONIC PANCREATITIS 
Chronic pancreatitis is progressive irreversible damage of the 
pancreas due to chronic inflammation. 
It can be 1. Chronic relapsing pancreatitis 
               2. Chronic persistant pancreatitis with or without calcification in 
the  duct or in the parenchyma 
INCIDENCE 
Acute pancreatitis is the most common gastrointestinal discharge 
diagnosis in the United States (274,119 patients in 2009), an incidence 
which has increased 30% since 2000, and is associated with the highest 
aggregate inpatient costs at 2.6 billion dollars per year. The crude 
mortality rate of 1.0/100,000 ranks it as the 14th most fatal illness overall 
and the ninth most common non cancer gastrointestinal death. The 
highest incidence recorded in Finland and  United States.  The racial 
incidence of acute pancreatitis also shows significant variation related to 
the prevalence of etiological factors and ethnicity. 
The annual incidence of acute pancreatitis in Native Americans is 4 per 
100,000 population; in whites it is 5.7 per 100,000 population; 
and in blacks it is 20.7 per 100,000 population. Smoking is an 
independent risk factor for acute pancreatitis. Male preponderance of this 
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disease is more because of alcoholic etiology. Women also suffer from 
acute pancreatitis as gallstones occur in higher frequency. 
AETIOLOGY  AND  PATHOLOGY OF ACUTE PANCREATITIS 
1. Gall stone- common cause 
2. Alcohol 
3. External trauma 
4. After ERCP,biliary, gastric and splenic surgery. 
5. Drugs-Corticosteroids such as prednisolone, diuretics (thiazides), 
HIV drugs such as didanosine and pentamidine, Anticonvulsant  
(Valproic acid), Chemotherapeutic drugs such as azathioprine and 
L-asparaginase, estrogen, antihyperglycemic agents like 
metformin, vildagliptin and sitagliptin. 
6. Infections-Viral-Mumps,Coxsackie,Hepatitis B Bacteria, 
Legionella, Leptospira, Mycoplasma, Salmonella  Fungi-
Aspergillus Parasites- Ascaris, Clonorchis sinensis, 
Cryptosporidium, Toxoplasma.  
7. Autoimmune disease 
8. Hypercalcemia states arising from hyperparathyroidism, 
Hyperlipidemia 
9. Diabetes. 
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10. Pancreatic duct obstruction by neoplasm, pancreas divisum, 
ampullary and duodenal lesions. Less common causes include 
pancreatic duct stones, vasculitis of small vessels of pancreas, 
porphyria, scorpion sting(sting of the Trinidadian scorpion Tityus 
ntrinitatis which causes neurotransmitter discharge from 
cholinergic nerve terminals, leading to massive production of 
pancreatic juice, idiopathic.  
 
                     
 
                               Fig.11.A,B Traumatic pancreatic injury. 
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PATHOLOGY OF ACUTE PANCREATITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12.Pathogenesis of acute pancreatitis 
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GALLSTONES 
The main pathology of acute pancreatitis caused by the gallstone 
disease and other conditions is the obstructed pancreatic duct by gall 
stones causing ductal hypertension.  This ductal hypertension cause the 
smaller ductules  to break and leak the pancreatic secretions into the 
substance of the pancreas. 
In response to ductal obstruction, proteolytic enzymes are activated 
in the pancreas. The endogenous pancreatic trypsin inhibitor counter 
small amounts of trypsin. However, destruction of acinar cells occurs due 
to large amounts of trypsin release and activation of other enzymes. 
 
 
 
Fig.13.Gallstones in pancreatic duct 
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INTRAPANCREATIC EVENTS 
Focus of tissue injury attract the activated neutrophils and after 
activation, release superoxides (the “respiratory burst”) and proteolytic 
enzymes  (cathepsins, elastase and collagenase)  which cause further 
injury. The activation of digestive enzyme causes rupture of capillaries  
and release of amylase, lipase, lecithinase, lysolecithinase, 
prostaglandins, bradykinins, kallikrein, free radicals, interleukin (IL-6, 
and IL-8), tumour necrosis factor- alpha, platelet activation factor. 
These inflammatory mediators cause the vascular permeability of 
the pancreas to increase, leading to edema, fluid collection, hemorrhage, 
and microthrombi. This results in pancreatic hypoperfusion and necrosis, 
a feature of more severe acute pancreatitis.  The interstitital edematous 
pancreatitis is the acute inflammation of the pancreatic parenchyma and 
peripancreatic tissues without necrosis. 
Necrotizing pancreatitis is acute inflammation of pancreas with 
necrosis evidenced by pancreatic hypoperfusion with contrast CT. 
The updated morphological definitions and the contrast enhanced 
CT criteria for the diagnosis of the local complications of acute 
pancreatitis have recently been published in the revised Atlanta statement. 
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Phospolipase A2 activation causes pulmonary surfactant destruction 
resulting in liberation of leucotrienes and ARDS. 
This is the cause for systemic inflammatory response syndrome 
(SIRS) resulting in multi organ failure (MOF).  When gallstones and 
other etiological factors cannot be identified there is still the possibility of 
finding microlithiasis, seen as birefringent crystals, on bile microscopy.30 
ALCOHOLIC PANCREATITIS 
The amount of alcohol consumed (typically 100 to 150 grams per 
day) and the pattern of drinking is important rather than the type of 
alcohol for the cause of acute pancreatitis. Ethanol,which is the metabolic 
toxin causes a brief secretory increase  followed by inhibition, spasm of 
the sphincter of Oddi,  ductal permeability resulting in acute pancreatitis. 
Ethanol also increases the protein content of pancreatic juice, decreases 
bicarbonate levels, and trypsin inhibitor concentration. 
IATROGENIC 
5% to 10% of ERCP causes acute pancreatitis as a complication 
and it is the third most common identified etiological factor.  Surgeries 
resulting in acute pancreatitis are pancreatic biopsy, exploration of the 
extrahepatic biliary tree and ampulla of Vater, distal gastrectomy, 
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splenectomy, colectomy,  nephrectomy, aortic aneurysmorraphy,  and 
retroperitoneal lymphadenectomy. 
PANCREATITIS DUE TO FAMILIAL ETIOLOGY 
It is an autosomal dominant disorder due to trypsinogen gene 
mutation (PRSS1),and SPINK1 protein mutation.  
HYPERLIPIDEMIA  
Lipase is thought leading to microcirculatory impairment and 
ischemia,mainly in patients with types I and V hyperlipoproteinemia 
associated with hypertriglyceridemia to liberate toxic fatty acids into the 
pancreatic microcirculation,. 
DIAGNOSIS 
The first step to make the diagnosis is eliciting the detailed history 
and careful physical examination. If the patient has a history of  colicky 
pain and binge alcohol consumption,acute pancreatitis should be 
suspected. 
 
 
 
 
 
 
 
30 
 
CLINICAL FEATURES: 
SYMPTOMS:   
 Abdominal pain 
Sudden onset of epigastric pain which is severe constant in 
nature radiating to the  back, relieves by leaning forward 
 
         
 
 
Fig.14.Typical posture for pain relief 
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 Nausea 
 Vomiting 
 Anorexia 
 Diarrhoea 
 Loss of appetite 
SIGNS: 
 Fever or Chills 
 Tachycardia 
 Hypotension 
 Abdominal tenderness 
 Muscular guarding in upper abdomen 
 Abdominal distension 
 Diminished or absent bowel sounds because of ileus 
 Jaundice in few cases 
 Dyspnoea due to irritation of diaphragm, pleural effusion (left side) 
and ARDS 
 Severe cases  will develops hemodynamic instability, hematemesis, 
malena, pallor. Muscular spasm in the extremities may be noted 
secondary to hypocalcemia 
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      Physical findings of severe necrotizing pancreatitis 
 Cullen’s sign – bluish discolouration around the umbilicus due to 
hemoperitoneum  
 
Fig.15. Cullen’s sign 
 Grey-Turner sign-reddish brown discolouration along the flanks 
due to retroperitoneal blood dissecting along tissue planes                   
               
Fig.16. Grey-Turner sign 
 Fox sign - Ecchymosis in the inguinal region 
Erythematous skin nodules  located on extensor skin surfaces results from 
focal subcutaneous fat necrosis. 
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INVESTIGATIONS 
LABORATORY TESTS 
 Routine blood investigations-Complete blood count, ESR, blood 
urea, serum creatinine, serum calcium and coagulation profile. 
 Serum amylase (Normal value-30-180IU/L) 
The level increases immediately with the disease onset  and reaches its 
peak level within several hours.  Severity of acute pancreatitis doesn’t  
correlates with raise of serum amylase level. Conditions causing 
hyperamylasemias other than acute pancreatitis are obstruction of small 
bowel,duodenal ulcer perforation, or other inflammatory conditions of the 
abdomen. Urinary amylase levels usually remain elevated for several 
days after serum levels have returned to normal. 
 Serum lipase which is more specific for pancreatitis remain raised 
for  longer as it has a longer half life than amylase. 
 Liver function tests: 
        AST (Aspartate aminotransferase), ALT (alanine aminotransferase),            
GGT( gamma-glutamyl Transpeptidase ), serum bilirubin and alkaline 
phosphatase are the tests to differentiate  the  biliary etiology from other 
causes of pancreatitis. 
 A variety of single serum parameters, such as C-Reactive 
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Protein (CRP), alpha1-antitrypsin, polymorphonuclear (PMN) 
elastase,phospholipaseA2,  beta2-macroglobulin, trypsinogen 
activation peptide procalcitonin, tissue necrosis factor alpha and 
interleukin 6 and 8 have been investigated and found to be useful 
markers of the severity of acute pancreatitis. Among these biochemical 
indicators, the most widely and the simplest available test is CRP.  
 C-Reactive Protein (CRP) 
CRP is a ring shaped acute-phase protein produced by the liver and found 
in plasma which is raised as a result of macrophages and T cells 
activation causing interleukin-6 secretion in inflammation. 
CRP is a substance that first identified in patients serum with acute 
inflammation. It is named as it has reacted with Pneumococcus  somatic 
'C' carbohydrate antigen. 
In 1930, Tillett and Francis discovered  CRP.  The first 
chromosome (1q21-q23) is the location of the CRP gene. Upon activation 
of complement system, by binding of  CRP  to the phosphocholine which 
is expressed on the surface of inflammed cells, necrotic and apoptotic 
cells are cleared by macrophages which promotes  phagocytosis.  Normal 
value of CRP concentration in healthy adults is below10 mg/l. CRP raises 
in inflammation within two hours, and peaks at 48 hours with constant 
half-life of 18 hours, and therefore CRP is a marker for inflammation and 
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also predict the severity of the inflammation. Serum CRP levels above 
12~15 mg/dl correlate with severe disease. 
 CRP is a more sensitive than the ESR  (Erythrocyte Sedimentation 
Rate). CRP levels have been evaluated in terms of their ability to predict 
severity, necrosis and complications of  acute pancreatitis. A CRP level 
of less than or equal to 150mg/dl obtained at 72 hours is useful enough to 
rule out with high degree of probability the presence of necrosis in acute 
pancreatitis. 
 Alpha 1 Antitrypsin(AIAT) 
Alpha 1 Antitrypsin is a serum trypsin inhibitor belongs to serpin family 
synthesized by the liver. It protects the tissues from the action of 
neutrophil- protease enzymes of the inflammatory cells. Normal value of 
AIAT concentration in healthy adults ranges from 1.5 to 3g/l. Its level 
rises manyfold upon acute inflammation. Its gene is present in long arm 
of 14 chromosome (14q321). A1AT deficiency results in respiratory 
diseases like emphysema, COPD in adults and cirrhosis in adults or 
children due to break down of elastin by neutrophil elastase. Methods 
available to detect are enzyme linked immuno sorbent assays, radial 
immunodiffusion, turbidimetry, nephlometry. 
RADIOLOGIC IMAGING 
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 Plain X – ray chest PA View  
Left sided diaphragm elevation,  
Left sided Pleural effusion           
 Plain X-Ray Abdomen 
Mostly non specific findings.  Air will be seen in duodenal C-loop. 
Sentinel loop sign which is produced by focal dilatation of  proximal 
jejunum. X-ray also shows Colon cut off sign which is due to dilatation 
of colon upto transverse colon with less gas distal to splenic flexure.      
 
Fig.17 X-Rays of acute pancreatitis  
 
  
 
Renal halo sign 
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 In suspected biliary pancreatitis, Ultrasound of abdomen is the 
investigation of choice for confirming the presence of gallstones. It 
also identifies the extrapancreatic dilatation of the ducts, 
oedematous pancreas and peripancreatic collection of  the fluid.  
 
Fig. 18. Ultrasound  of  acute pancreatitis 
 
 CT Scan ( Computed Tomography ): CT is the investigation of 
choice next to ultrasound in acute pancreatitis. It detects the edema 
of  the pancreas, collection of the fluid, and it allows for the 
grading of severity of  acute pancreatitis. It also identifies the 
complications like pseudocysts, necrosis, infected necrosis and 
hemorrhage. 
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CT shows both pancreatic and peripancreatic findings. Pancreatic 
findings are focal or diffuse enlargement of pancreas, pancreatic edema 
and  necrosis. Peri pancreatic findings are thickening or blurring of 
adjacent tissues. The CT findings correlate well with the course and 
severity of the disease. 
Plain CT helps in diagnosis of the disease and reveals fluid 
collection but cannot identify the necrosis or vascular insult.  Contrast 
enhanced CT helps in detecting  all complications such as fluid 
collection, pseudocyst, abscess, pseudoaneurysm. Infected necrosis or 
abscess is indicated by air bubbles in CE-CT. This scan can also helps for  
diagnostic fine needle aspiration or placement of pigtail catheter.  
 
  
 
Fig. 19.CT scan  of  acute biliary pancreatitis 
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 Magnetic Resonance Cholangiopancreatography (MRCP): MRCP 
predict the severity of pancreatitis as same as CE- CT. It also 
identifies the necrosis of the pancreas, but for the detection of 
small stone it is less sensitive.  
 
Fig.20. Sigmoid configuration of main pancreatic duct with 
obstruction of  papilla. 
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 Endoscopic Ultrasonography: It is the better investigation for obese 
patients. It also helps to identify the patient for whom therapeutic 
ERCP would be  beneficial.  
 
Fig.21.ERCP 
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SCORING SYSTEMS 
For proper decisions of management, it is important to predict the 
severity of acute pancreatitis. Decisions of management depends on 
whether a  patient  should be admitted to an intensive care unit, or 
transferred to a tertiary hospital, and whether an ERCP is needed, or 
about necessity of fluid therapy, and other issues. The most widely used 
prognostic criteria is the Ranson’s criteria (Table 3). 
This score uses clinical and biochemical parameters in the first 48 
hours of admission. The disease is “predicted severe”, when there are 3 or 
more positive criteria. Other scoring systems for predicting severity are 
Bedside Index for Severity of Acute Pancreatitis (BISAP),an APACHE II 
score of 8 or more at 24 hours after admission, CT severity index 
(CTSI),SOFA score, a serum C-Reactive Protein level of >150mg/dl also 
predict the severity with similar accuracy as Ranson’s criteria.  
Ranson identified 11 objective parameters, out of these, five are 
measured at the time of admission,the remaining six are measured within 
48 hours of admission. 
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Table - 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
Table – 4  Glasgow Imrie criteria for acute pancreatitis 3 or more of the 
below in first 48 hours indicates a severe attack. 
Pao2 < 8 KPa 
Age >55 years 
Neutrophils >15x109/L  
Calcium >2 mmol/L 
Renal function Urea>16mmol/L 
Enzymes LDH>600 IU/L, 
AST>2000 IU/L 
Albumin <32g/L 
Sugar Glucose>10mmol/L 
 
 
Table – 5 BISAP SCORE
 
 
 
 
Table - 6 
The acute physiology and chronic health evaluation (APACHE-II) score 
A.ACUTE PHYSIOLOGY SCORE 
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Total acute physiology score(sum of 12 above points) 
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Table – 7 
 
C.CHRONIC HEALTH POINTS IN APACHE II 
 
HISTORY 
POINTS FOR 
ELECTIVE 
SURGERY 
POINTS FOR 
EMERGENCY 
SURGERY 
Proven liver cirrhosis,portal 
hypertension or liver failure 2 5 
Cardiovascular NYHA grade IV 2 5 
Respiratory eg:COPD, pulmonary 
hypertension 2 5 
Chronic renal disease 2 5 
Immunocompromised 2 5 
 
Total APACHE II Score is the sum of points from A+B+C 
Score 0 to 2 : 2 %    mortality 
Score 3 to 4 : 15%   mortality 
Score 5 to 6 : 40%   mortality 
Score 7 to 8 : 100% mortality 
 
In 1991, APACHE III SCORE was released with the aim to improve 
statistical power, predict  the patient outcome and to identify factors in 
ICU which influence outcome variations. 
Parameters includes 17 physiological variables and Total score (0-299), 
acid base disturbances, GCS Score-based on the worst, Age score, 7 Co-
morbidities (cardiac, respiratory and renal failures excluded). 
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In 1985, Balthazar  introduced  CT severity index for  determining the 
morphologic severity of acute pancreatitis. 
Table-8. Scoring for pancreatic necrosis
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Table-9.  Modified CT severity indexEvaluation of pancreatic 
morphology, without taking into account the extent of pancreatic necrosis
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CT SEVERITY SCORE: 
Score 0-     :  3%   mortality 
Score 4-6   :  6%   mortality 
Score 7-10 :  17% mortality 
Organ failure is scored using the Marshall or Sequential Organ Failure 
Assessment (SOFA) systems. 
 
 Multiple organ failure is defined as two or more organs registering 
2 or more points on these scoring systems. The three organ systems most 
frequently involved are cardiovascular, respiratory, and renal. Monitoring 
organ failure over time and in response to treatment is important in the 
clinical care of the disease. 
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Table – 10 SOFA-Sequential organ failure assessment score in acute 
pancreatitis
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Table-11 .Scoring system to assess severity of acute pancreatitis 
 
MILD TO MODERATE AP SEVERE AP 
Ranson signs              ≤ 3 Ranson signs             > 3 
APACHE II score      ≤ 8 APACHE II score     > 8 
CRP                           < 100 mg/l CRP                           >100 mg/l 
Balthazar’s CT score ≤ 3 Balthazar’s CT score > 3 
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TREATMENT 
The patient should be admitted in the hospital. The diagnosis  
should be established with clinical features, laboratory investigations and 
imaging studies.  
 Pain must be controlled using NSAIDS for mild patients and 
opioid analgesics in severe cases. 
Fluid therapy should be initiated with ringer lactate, normal saline, 
dextrose, plasma, fresh blood transfusion/packed cells, as there is lot of 
fluid  sequestration and third space loss . Ringer lactate solution is found 
to be superior to normal saline in reducing the systemic inflammatory 
response on the basis of recent data.  
Continuous nasogastric aspiration, urinary catheterization should 
be done for monitoring urine output 50 ml hourly.  Enteral  nutrition 
should be started early after fluid therapy within first 24 hours  of 
admission through nasogastric tube.  
Antibiotics such as third generation cephalosporins are of no 
proven value unless otherwise suspected infection. 
 For preventing stress ulcers iv Pantoprazole 80mg bd should be 
given.   
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Frequent examination of  the patients and serial measurement of 
inflammatory markers is the must for identification of early complication.   
CECT should be ordered for suspected complicated cases.   
For severe cases, intervention should be carried out  invasively.  
The treatment for biliary pancreatitis is cholecystectomy and clearance of 
common duct by ERCP if stone is present in CBD.  If there is persistence 
of obstruction after 24 hours,it leads to biliary sepsis,  so emergency 
ERCP has to be done. 
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COMPLICATIONS 
Both local and systemic complications can occur in acute pancreatitis. 
Table-12   Local complications of acute pancreatitis39 
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Table - 13    Systemic complications 
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Table-14 Four categories of acute pancreatitis severity based on 
organ failure and local complications
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AIMS AND OBJECTIVES 
 
Primary objective is study on C-Reactive Protein for assessing and 
monitoring the  severity of acute pancreatitis. 
 
  
 
 
 
 
57 
 
METHODS AND MATERIALS 
TITLE 
Study on C- Reactive Protein-an aid for assessing and monitoring the 
severity of acute pancreatitis in Government Mohan 
Kumaramangalam Medical College, Salem 
SOURCE OF DATA:  
All  Patients with acute pancreatitis who admitted in department of 
general surgery in Government Mohan Kumaramangalam Medical 
College Hospital. 
SAMPLE SIZE: 
Sample size of 75 patients fulfilling the inclusion criteria. 
METHOD OF COLLECTION OF DATA: 
The data was collected by thorough history taking, clinical examination 
and investigations. 
STUDY DESIGN 
Prospective study 
STUDY PERIOD 
June 2015 - June 2016 
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PLACE OF THE STUDY 
Govt.  Mohan Kumaramangalam Medical College Hospital, Salem. 
ETHICAL CLEARANCE 
Ethical clearance obtained from the institution ethical committee 
Inclusion criteria: 
Patients with acute Pancreatitis admitted in general surgery ward 
Exclusion criteria: 
1.Patients admitted with acute pancreatitis who are associated with  
comorbid disease  at the time of admission. 
2.Patients who come with complications of acute pancreatitis 
3.Patients with chronic pancreatitis                             
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STUDY METHODOLOGY 
In this study, prior written informal consent was obtained from the 
patients admitted with acute pancreatitis. Data such as detailed history 
taking and complete clinical examination was noted on a pretested 
proforma. All patients were subjected to following investigations.  
Complete blood count, Blood sugar, urea,  
Serum creatinine, serum electrolytes, Urine routine examination,  
Serum Amylase, Serum Lipase 
C Reactive Protein, Alpha 1 Antitrypsin,  
ECG in all leads, Chest X ray PA view and/or USG Thorax, 
Ultrasound Abdomen,  
Relevant special investigation: CT Abdomen-Plain/Contrast 
• The details of the above were given in the clinical proforma sheet 
and in the master chart. 
The results are evaluated and analyzed by comparing with serial 
monitoring of alpha 1 antitrypsin. White cell count, erythrocyte 
sedimentation rate, temperature were used as reference data. 
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RESULTS 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version. To describe about the data descriptive statistics mean & S.D 
were used for continuous variables. To find the significant difference 
between the bivariate samples in  Independent groups the Unpaired 
sample t-test was used. The logistic regression model with forward 
stepwise (Wald) method was used to find the influence of variables in the 
severity of disease. 
In both the above statistical tools the probability value .05 is considered 
as significant level. 
P - Value** Highly Significant at P ≤ .01 
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Chart – 1 ESR mean of mild & severe AP 
The mean ESR of mild cases was found about 24.81 
The mean ESR of severe cases was 48.95 which is more than mild cases 
and found statistically significant (P<0.001) 
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Chart – 2 Temperature mean of mild & severe AP 
The mean temperature of mild cases was found about 98.13 
The mean temperature of severe cases was about 98.57 
It was found statistically significant (P<0.001) 
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Chart – 3 Alpha 1 Antitrypsin mean of mild & severe AP 
The mean Alpha 1 Antitrypsin of mild cases was found about 2.68 and 
the same for severe cases was about 3.64,  which is more than mild cases 
and was also found statistically significant (P<0.001) 
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Chart – 4 CRP mean of mild & severe AP 
The mean  CRP  of mild cases was found about 34.26 and the same for 
severe cases was about 98.04, which is more than mild cases and it was 
also found statistically significant (P<0.001). 
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Chart – 5  WBC mean of mild & severe AP 
The mean WBC  of mild cases was found about 10487.61 and the same 
for severe cases was about 13443.52 which is more than mild cases and it 
also found statistically significant (P<0.001). 
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Table - 15 
Group Statistics 
Statistics of mean values of  inflammatory markers 
MS N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
ESR 
MEAN 
Mild 39 24.81 6.71404 1.07511 
Severe 36 48.95 6.51343 1.08557 
TEMP 
MEAN 
Mild 39 98.13 .26342 .04218 
Severe 36 98.57 .52459 .08743 
AA 
MEAN 
Mild 39 2.6778 .32217 .05159 
Severe 36 3.6432 .56599 .09433 
CRP 
MEAN 
Mild 39 34.26 8.42058 1.34837 
Severe 36 98.04 18.84195 3.14033 
WBC 
MEAN 
Mild 39 10487.61 1022.1 163.7 
Severe 36 13443.52 691.6 115.3 
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Table - 16 
T – Test  Statistics 
 
 
 
 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t Df Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
ESR 
MEAN 
Equal 
variances 
assumed 
1.311 .256 -15.785 73 .0005 -24.14601 1.52973 -27.19475 -21.09727 
Equal 
variances 
not 
assumed 
  -15.804 72.812 .000 -24.14601 1.52785 -27.19114 -21.10088 
TEMP 
MEAN 
Equal 
variances 
assumed 
29.522 .000 -4.657 73 .0005 -.44124 .09475 -.63008 -.25240 
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Equal 
variances 
not 
assumed 
  -4.545 50.660 .000 -.44124 .09708 -.63616 -.24632 
AA MEAN 
Equal 
variances 
assumed 
2.913 .092 -9.168 73 .0005 -.96546 .10531 -1.17535 -.75558 
Equal 
variances 
not 
assumed 
  -8.980 54.570 .000 -.96546 .10752 -1.18097 -.74996 
CRP 
MEAN 
Equal 
variances 
assumed 
3.815 .055 -19.175 73 .0005 -63.78063 3.32631 -70.40996 -57.15129 
Equal 
variances 
not 
assumed 
  -18.663 47.605 .000 -63.78063 3.41757 -70.65358 -56.90768 
WBC 
MEAN 
Equal 
variances 
assumed 
4.570 .036 -14.545 73 .000 -2955.9 203.2 -3360.9 -2550.9 
Equal 
variances 
not 
assumed 
  -14.766 67.114 .0005 -2955.9 200.2 -3355.5 -2556.4 
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Day wise ESR mean values of mild and severe cases 
 
Mild Severe 
Day 1 37.05 71.94 
Day 3 31.13 63.50 
Day 5 27.69 55.50 
Day 7 22.00 44.75 
Day 9 17.05 34.28 
Day 11 13.92 23.75 
 
 
 
Chart - 6 
The mean value of ESR  for severe acute pancreatitis on day 1,was 71.94 
and the same for mild attack was 37.05, and both were found raised than 
normal value on day 1. 
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The mean values of ESR for both severe and mild attacks were declined 
on days 3,5,7,9,11 and the values were found almost the same by         
day 11. 
Day wise Temperature  mean values of mild and severe cases 
 
Mild Severe 
Day 1 98.26 99.36 
Day 3 98.31 99.33 
Day 5 98.21 98.64 
Day 7 98.00 98.08 
Day 9 98.00 98.00 
Day 11 98.00 98.00 
 
 
Chart - 7 
The mean temperature of severe acute pancreatitis on day 1,was 99.36 
and the same for mild attack was 98.26,and both were found raised on 
day 1. The mean temperatures of both severe and mild attacks  declined 
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on days 3,5,7,9  and the patient was afebrile  by day 9 in both groups. 
Here also, differences were  narrow  by the end of day 9. 
Day wise Alpha 1 Anti-Trypsin  mean values of mild and severe cases 
 
Mild Severe 
Day 1 3.21 4.44 
Day 3 3.15 4.22 
Day 5 2.96 4.05 
Day 7 2.57 3.49 
Day 9 2.16 3.00 
Day 11 2.02 2.71 
 
 
Chart - 8 
The mean value of Alpha 1 Antitrypsin for severe acute pancreatitis on 
day 1,was 4.44  and the same for mild attack was 3.21,and both were 
found raised on day 1 found statistically significant (P<0.001). 
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The mean values of Alpha 1 Antitrypsin for both severe and mild attacks 
were decreased on days 3,5,7,9,11 and the values were almost the same 
by day 11. 
Daywise C-Reactive Protein mean values of mild and severe cases 
 
Mild Severe 
Day 1 48.97 114.47 
Day 3 55.23 137.17 
Day 5 44.36 117.58 
Day 7 30.62 92.03 
Day 9 17.90 69.37 
Day 11 8.46 48.60 
 
 
Chart - 9 
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The CRP mean value for severe acute pancreatitis on day 1,was 114.47  
and the same for mild attack was 48.97,and both were found raised on 
day 1 which was statistically significant(p<0.001) 
The mean values of CRP for both mild and severe acute 
pancreatitis were found raised on day 3 than the first day, started 
declining on days 5, 7,9,11.  Increase of CRP values was more in patients 
with severe disease than with mild disease. But the rate of fall of CRP 
was slow in severe acute pancreatitis and on day 11 difference of values 
between the two attacks were in a wide range.   
  
 
 
 
 
74 
 
Day wise C-Reactive Protein mean values of mild and severe cases 
 
Mild Severe 
Day 1 10697.44 13936.11 
Day 3 10738.46 13911.11 
Day 5 10743.59 13877.78 
Day 7 10310.26 13077.78 
Day 9 10225.64 12936.11 
Day 11 10210.26 12922.22 
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The WBC mean value for severe acute pancreatitis on day 1, was 
13936.11cells per cubic millimeters of blood and the same for mild attack 
was 10697.44 cells/cu.mm ,and both were found raised on day 1. The 
values decreased on days 3, 5, 7,9,11.  By the end of first week there was 
narrow range of differences in severe and mild disease. 
Logistic Regression 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected 
Cases 
Included in 
Analysis 75 100.0 
Missing Cases 0 0.0 
Total 75 100.0 
Unselected Cases 0 0.0 
Total 75 100.0 
a. If weight is in effect, see classification table for the total number of 
cases. 
Dependent Variable Encoding 
Original 
Value Internal Value 
Mild 0 
Severe 1 
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Classification Table 
Observed 
Predicted 
 
 
Mild Severe Percentage Correct 
Step 0 MS Mild 39 0 100.0 
  
Severe 36 0 0.0 
 
Overall Percentage   52.0 
a. Constant is included in the model. 
b. The cut value is .500 
Variables in the Equation 
 B S.E. Wald df  Sig Exp(B) 
Step 0 
Constant 
-.080 .231 .120 1 .729 .923 
 
Variables not in the Equation 
  Score df Sig. 
Variables 
AGE .016 1 .899 
ESR MEAN 58.005 1 .000 
TMP MEAN 17.177 1 .000 
AA MEAN 48.706 1 .000 
CRP MEAN 62.576 1 .000 
WBC MEAN 55.759 1 .000 
Overall Statistics 67.141 6 .000 
Block 1: Method = Forward Stepwise (Wald) 
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Omnibus Tests of Model Coefficients 
 
 
Chi-square Df Sig. 
Step 103.852 1 .000 
Block 103.852 1 .000 
Model 103.852 1 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & 
Snell R 
Square 
Nagelkerke R 
Square 
1 .000a .750 1.000 
 
a. Estimation terminated at iteration number 20 because maximum 
iterations has been reached. Final solution cannot be found. 
 
Classification Table 
 
Observed 
Predicted 
MS Percentage 
Correct Mild Severe 
Step 1 
MS 
Mild 39 0 100.0 
  0 36 100.0 
 Overall Percentage    
 
a. The cut value is .500 
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B S.E. Wald df Sig. Exp(B) 
Step 
1 
CRP 
MEAN 
7.229 284.254 .001 1 .980 1379.5 
Constant -480.861 18989.697 .001 1 .980 .0 
 
a. Variable(s) entered on step 1: CRPMEAN. 
b. Stepwise procedure stopped because removing the least significant 
variable result in a previously fitted model. 
 
Variables not in the Equation 
  Score df Sig. 
Variables AGE .000 1 .998 
ESR MEAN .003 1 .960 
TMP MEAN .171 1 .679 
AA MEAN .001 1 .975 
WBC MEAN .006 1 .939 
 
a. Residual Chi-Squares are not computed because of redundancies. 
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Descriptives 
Groups = Mild 
 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 39 19 65 38.46 9.894 
Valid N 
(listwise) 
39         
 
a. Groups = Mild 
 
Descriptive Statistics 
 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 36 14 65 38.17 10.457 
Valid N 
(listwise) 
36         
 
a. Groups = Severe 
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DISCUSSION 
In our study of 75 patients of acute pancreatitis, 39 patients were 
found to have mild disease and 36 patients were found to have severe 
acute pancreatitis according to Atlanta criteria 2012. Etiologies of the 
disease were alcoholic, biliary and idiopathic. 
In 1984, Mayer et al. studied the CRP role in the assessment and  
monitoring of acute pancreatitis and found that the main value of CRP 
provided guide to the severity of inflammation.  They also found that 
when the CRP value remain high (> 100 mg/l) at the end of the first week 
of the illness there is risk of developing pancreatic collections. 
In 1984, McMahon et al. found low levels of CRP in patients with 
mild pancreatitis and high values in patients with severe pancreatitis. 
Samples for CRP, Alpha 1 Antitrypsin, WBC, and ESR were 
collected on day1 of admission and on days 3, 5, 7, 9, 11 after admission. 
Temperature, ESR, Alpha1Antitrypsin values didn’t discriminate acute 
pancreatitis as mild and severe disease.  Although those values were high 
in severe acute pancreatitis, mean 95% confidence limits of mild and 
severe attacks were overlapped throughout the study. 
On day 1 of admission, difference in WBC count between mild and 
severe disease, helps to discriminate between the two. As the disease 
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progressed, CRP values reaches maximum in the end of first week, in 
severe acute pancreatitis and it takes more time to fall towards normal 
value.  Hence CRP helped to differentiated between mild and severe 
acute pancreatitis better than WBC and Alpha 1 antitrypsin value.  High 
level of CRP (>100mg /l) at first week suggests that patients who have 
the disease requires 2 or more weeks to recover and there is risk of 
developing pancreatic collection.  
Increased values of CRP reflect severe local inflammation in mild 
disease with benign clinical course. 
Hence, CRP is a sensitive indicator of continuing inflammation and 
it may be of  better value in selecting the cases who are more prone for 
developing high risk complications. 
We followed the patient,in due course we found the following results 
OUTCOME NUMBER OF PATIENTS 
Improvement 39 
Worsening of the disease 15 
Multiorgan failure 2 
Needing surgical intervention for acute 
Pancreatitis 7 
Chronic pancreatitis 20 
Death 1 
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CONCLUSION 
Temperature, ESR, Alpha1Antitrypsin values didn’t discriminate 
acute  pancreatitis as  mild or severe disease.  Although those values 
found high in severe acute pancreatitis, mean 95% confidence limits of 
mild and severe attacks were overlapped throughout the study. 
Of the inflammatory markers studied, CRP was able to 
differentiate acute pancreatitis into mild and severe forms  with greatest 
precision.   
PATIENT WITH ACUTE PANCREATITIS 
 
 
 
PANCREATIC NECROSIS 
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PATIENT CONSENT FORM 
 
STUDY TITLE                                                                                                   
  STUDY ON C REACTIVE PROTEIN – AN AID FOR ASSESSING 
AND MONITORING THE SEVERITY OF ACUTE 
PANCREATITIS IN GMKMCH SALEM   
   Department of General surgery , GMKMCH SALEM 
 
PARTICIPANT NAME :   AGE :  SEX: 
  
I.P. NO : 
              I confirm that I have understood the purpose of investigation/surgical  
procedure  for the above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my satisfaction. 
I have been explained about the possible out comes  that may occur during  
and after providing  nutrition. I understand that my participation in the study is 
voluntary and that I am free to withdraw at any time without giving any reason. 
I understand that investigator, regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study. I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from the study. 
I hereby consent to participate in this study for  various investigation /surgical 
procedures and their outcomes. 
Date / 
Time :                                      Signature / Thumb Impression Of Patient                                                   
Place :                                                       
          Patient name :  
  
        
Signature of the investigator: 
 
Name of the investigator :                                                                                   
 
  
           PROFORMA 
 
NAME: 
ADDRESS: 
 
AGE/SEX:   
RELIGION: 
O.PNo:   
I.P No:                                                                                   
D.O.A:            
                                                                                                                                                                        
TIME & DATE OF OPERATION: 
D.O.D: 
B. CHIEF COMPLAINTS: 
 C.PAST HISTORY: 
1. DM                            : Yes/ No 
2. TB                              : Yes/ No 
3. CARDIAC DISEASE 
4. BRONCHIAL  ASTHMA                                      
5. PREVIOUS SURGERY,PREVIOUS  H/O  ACUTE 
PANCREATITIS 
6. JAUNDICE 
7. CIRRHOSIS 
 
D.PERSONAL HISTORY: 
SMOKER 
ALCOHOLIC 
E.INITIAL ASSESSMENT OF PATIENT 
 1.VITALS: 
            PR                : 
            BP                :  
            RR                :     
            Temperature : 
2.GENERAL SIGNS:        
                                                                                                                                                         
               Pallor 
               Tongue 
               Skin  
               Icterus 
               Cyanosis  
               Lymphadenopathy:                                                                                                                                         
F. Assessment of   abdomen                                    
1)INSPECTION:                                                                              
a) shape of the abdomen                                                                                               
b)skin                                                                        
c)umbilicus                                                       
d)movement of the abdomen –respiratory ,peristaltic                                                                       
e)swelling                                                                                                                                                                
f)Hernial orifices                                                                                                                                                           
2) PALPATION                                                                                                                                 
a)Temperature                                                                                                                             
b)Tenderness                                                                                                                             
c)Distension                                                                                                                                    
d)Palpation of mass                                                                                                                      
e)Palpation of abdominal organs                                                                                                                
f)Muscle guard                                                                                                                                  
g)Palpation of hernia sites                                                                                                               
           
                                                                                                                              
3)PERCUSSION         
                                  
4)AUSCULTATION          
    Bowel sounds                                                                                                                                   
G)   Examination of left supraclavicular  lympnodes 
H)  EXTERNAL GENITALIA 
I)   PER RECTAL EXAMINATION      
                                                                                                                     
J)    SYSTEMIC EXAMINATION: 
CVS 
RS 
CNS 
MUSCULO SKELETAL SYSTEM 
 
CLINICAL DIAGNOSIS 
 
INVESTIGATIONS 
A. COMPLETE BLOOD PICTURE – HB, 
PCV,TC,DC,ESR,RBC,PLATE LET 
B.  BLOOD GROUPING & TYPING 
C. BT/CT 
D. SERUM AMYLASE ,SERUM LIPASE,                                                                                                                  
C-REACTIVE PROTEIN – TIME OF ADMISSION ,EVERY  48 
HRS TILL THE LEVEL DECREASES 
E. ANTIPROTEASE:ALPHA1 ANTITRYPSIN ALONG WITH CRP 
F. HIV 
G. ECG 
H. URINE:                           Macro 
                                              Micro  
                                              Albumin 
                                              Sugar 
I. BLOOD: 
                                      RBS 
                                      BLOOD UREA 
                                      SER.CREATININE 
   
J. CHEST X RAY PA VIEW  :                                                                                                                            
X –RAY ABDOMEN ERECT: 
K. ABDOMEN & PELVIS  USG                                                                                                                                                                                                                                                                       
C.T ABDOMEN-PLAIN /CONTRAST 
DIAGNOSIS: 
  
OUTCOME OF THE TREATMENT: 
1.IMPROVEMENT  
2.WORSENING OF DISEASE 
3.MULTIORGAN FAILURE 
4.NEEDING SURGICAL INTERVENTION – PSEUDOCYST, 
NECROSECTOMY 
5.CHRONIC PANCREATITIS 
6.DEATH 
MEDICAL / SURGERY: 
 
DA
Y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
1 Perumal 35 47048 1 34 28 20 16 10 12
2 Vijay 35 51792 1 30 24 20 18 10 10
3 Murugaiya 55 54678 1 34 26 20 16 10 10
4 Karthi 40 56582 2 60 50 40 38 28 22
5 Saravanan 30 58444 1 30 28 22 16 10 14
6 Iyappan 28 60936 1 28 24 28 14 10 12
7 Peraman 43 19115 1 32 30 26 20 11 10
8 Govindasamy 40 63640 2 68 52 48 34 30 26
9 Madesh 35 79736 2 70 60 50 48 36 24
10 Selvamani 56 81720 2 82 64 48 36 28 16
11 Madesh 38 84358 1 30 28 20 18 14 10
12 Thangaraj 45 85698 2 56 48 50 40 32 28
13 Selvaraj 50 36118 1 30 24 20 18 16 10
14 Parameshwaran 35 86030 1 34 20 20 16 12 10
15 Jeevasubramanian 42 86370 1 36 26 26 18 14 12
16 Nagaraj 28 87968 1 40 32 28 16 10 8
17 Ilayaraja 36 97934 1 42 36 30 18 14 10
18 Chandrasekaran 40 89344 1 40 30 26 20 16 12
19 Jayaraman 35 88222 2 68 54 48 34 28 14
20 Om prakash 29 39010 1 34 24 30 16 14 12
21 Peter 45 91358 2 78 62 50 48 36 24
22 Raja 23 94090 1 30 24 20 18 16 10
23 Manivel 30 96052 2 60 58 60 52 48 32
24 Raju 45 96158 1 38 26 20 18 20 14
25 Loganathan 43 97715 2 78 60 58 42 30 18
26 David 25 25347 2 100 96
27 Ramachandran 45 98320 1 30 26 22 18 14 10
28 Raja 45 99158 2 96 84 78 60 42 24
29 Arivalagan 44 99326 2 98 86 60 52 34 26
30 Sivasankar 19 100222 1 80 70 58 38 30 22
31 Ramesh 36 100308 2 74 70 68 48 34 20
32 Muthusamy 37 100684 2 60 58 48 40 32 24
33 Basha 35 101108 1 30 26 20 18 10 12
34 Muthukumar 14 100800 2 58 44 38 40 30 26
35 Kumar 42 102500 1 32 28 30 26 20 14
36 Velmurugan 25 103640 2 48 50 42 36 26 20
37 Murugesan 40 105182 1 41 30 24 20 18 16
38 Prakash 36 106336 1 34 28 24 20 18 16
39 Jayaprakash 35 110726 2 60 54 50 48 30 15
40 Sivasubramaniyan 32 110734 1 30 26 30 26 16 10
ESR VALUES (mm / Hour)
S.NO Name AGE IP No MS
DA
Y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
ESR VALUES (mm / Hour)
S.NO Name AGE IP No MS
41 Arumugam 65 113706 1 40 32 36 28 18 12
42 Anandan 27 115890 2 60 54 48 36 30 20
43 Govindan 50 118184 1 30 32 28 20 18 14
44 Eswaran 40 23 1 34 30 24 20 20 18
45 Abinesh 24 828 1 40 34 28 20 20 16
46 Raja 40 386 1 70 62 50 48 40 31
47 Raju 40 40 2 60 62 54 44 36 24
48 Sudhakaran 50 4081 1 40 36 26 22 20 18
49 Madesh 35 6502 1 40 36 34 28 16 14
50 Selvakumar 40 7760 2 68 54 56 44 30 26
51 Yesudass 45 8642 2 72 68 64 56 40 20
52 Arjunan 27 1030 2 74 68 70 52 38 26
53 Thamaraikannan 27 9421 2 80 70 62 48 36 24
54 Shanmugam 43 11000 1 34 30 28 24 20 18
55 Rajivgandhi 32 12345 2 70 72 62 54 38 24
56 Murugan 50 14869 1 32 30 28 24 20 18
57 Murugesan 40 18034 1 40 30 28 20 18 14
58 Thangavel 60 22264 1 40 32 28 20 16 10
59 Raman 37 22300 2 68 70 64 56 48 38
60 Venkatesh 26 22579 1 38 34 30 28 18 16
61 Murugan 40 26890 2 78 74 68 50 46 30
62 Arumugam 36 26964 1 36 30 34 24 20 18
63 Vadivel 37 27048 1 34 38 32 36 24 20
64 Govindan 65 29541 2 70 68 58 42 38 26
65 Siva 30 29565 2 68 60 52 44 32 24
66 Kannan 31 30817 1 40 36 32 30 24 14
67 Arumugam 36 30990 2 70 60 52 43 34 26
68 Karupannan 65 34761 2 78 62 54 40 30 20
69 Tamilvannan 42 33581 2 70 62 50 40 30 20
70 Kuppusamy 45 34764 2 80 64 50 42 34 24
71 Dhamodharan 25 38129 2 72 64 52 42 34 24
72 Muthukaruppan 36 42136 2 88 68 54 44 36 24
73 Mani 40 32200 2 70 62 50 38 28 24
74 Vasanthakumar 45 34155 2 80 74 64 58 42 34
75 Senthil 32 391042 1 38 28 30 24 20 16
1 Perumal 35 47048
2 Vijay 35 51792
3 Murugaiya 55 54678
4 Karthi 40 56582
5 Saravanan 30 58444
6 Iyappan 28 60936
7 Peraman 43 19115
8 Govindasamy 40 63640
9 Madesh 35 79736
10 Selvamani 56 81720
11 Madesh 38 84358
12 Thangaraj 45 85698
13 Selvaraj 50 36118
14 Parameshwaran 35 86030
15 Jeevasubramanian 42 86370
16 Nagaraj 28 87968
17 Ilayaraja 36 97934
18 Chandrasekaran 40 89344
19 Jayaraman 35 88222
20 Om prakash 29 39010
21 Peter 45 91358
22 Raja 23 94090
23 Manivel 30 96052
24 Raju 45 96158
25 Loganathan 43 97715
26 David 25 25347
27 Ramachandran 45 98320
28 Raja 45 99158
29 Arivalagan 44 99326
30 Sivasankar 19 100222
31 Ramesh 36 100308
32 Muthusamy 37 100684
33 Basha 35 101108
34 Muthukumar 14 100800
35 Kumar 42 102500
36 Velmurugan 25 103640
37 Murugesan 40 105182
38 Prakash 36 106336
39 Jayaprakash 35 110726
40 Sivasubramaniyan 32 110734
S.NO Name AGE IP No
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1
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98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 101 100 98 98 98
98 98 98 98 98 98
99 99 99 98 98 98
99 99 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 102 101 99 98 98
98 98 98 98 98 98
100 101 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
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99 100 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
101 100 99 98 98 98
98 98 98 98 98 98
101 100 99 98 98 98
98 98 98 98 98 98
100 100 99 98 98 98
98 100 99 98 98 98
98 98 98 98 98 98
102 101
98 98 98 98 98 98
99 100 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 99 99 98 98 98
98 98 98 98 98 98
100 101 100 99 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 100 99 98 98 98
100 99 99 98 98 98
99 99 98 98 98 98
98 98 98 98 98 98
Temperature (Farenheit )
S.NO Name AGE IP No
41 Arumugam 65 113706
42 Anandan 27 115890
43 Govindan 50 118184
44 Eswaran 40 23
45 Abinesh 24 828
46 Raja 40 386
47 Raju 40 40
48 Sudhakaran 50 4081
49 Madesh 35 6502
50 Selvakumar 40 7760
51 Yesudass 45 8642
52 Arjunan 27 1030
53 Thamaraikannan 27 9421
54 Shanmugam 43 11000
55 Rajivgandhi 32 12345
56 Murugan 50 14869
57 Murugesan 40 18034
58 Thangavel 60 22264
59 Raman 37 22300
60 Venkatesh 26 22579
61 Murugan 40 26890
62 Arumugam 36 26964
63 Vadivel 37 27048
64 Govindan 65 29541
65 Siva 30 29565
66 Kannan 31 30817
67 Arumugam 36 30990
68 Karupannan 65 34761
69 Tamilvannan 42 33581
70 Kuppusamy 45 34764
71 Dhamodharan 25 38129
72 Muthukaruppan 36 42136
73 Mani 40 32200
74 Vasanthakumar 45 34155
75 Senthil 32 391042
DA
Y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
Temperature (Farenheit )
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 100 99 98 98 98
100 99 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
101 100 99 99 98 98
101 100 99 98 98 98
98 98 98 98 98 98
100 100 99 98 98 98
98 98 98 98 98 98
100 101 100 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
99 99 99 98 98 98
100 101 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 100 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
100 100 98 98 98 98
100 100 98 98 98 98
98 98 98 98 98 98
100 99 98 98 98 98
101 100 99 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
98 98 98 98 98 98
1 Perumal 35 47048
2 Vijay 35 51792
3 Murugaiya 55 54678
4 Karthi 40 56582
5 Saravanan 30 58444
6 Iyappan 28 60936
7 Peraman 43 19115
8 Govindasamy 40 63640
9 Madesh 35 79736
10 Selvamani 56 81720
11 Madesh 38 84358
12 Thangaraj 45 85698
13 Selvaraj 50 36118
14 Parameshwaran 35 86030
15 Jeevasubramanian 42 86370
16 Nagaraj 28 87968
17 Ilayaraja 36 97934
18 Chandrasekaran 40 89344
19 Jayaraman 35 88222
20 Om prakash 29 39010
21 Peter 45 91358
22 Raja 23 94090
23 Manivel 30 96052
24 Raju 45 96158
25 Loganathan 43 97715
26 David 25 25347
27 Ramachandran 45 98320
28 Raja 45 99158
29 Arivalagan 44 99326
30 Sivasankar 19 100222
31 Ramesh 36 100308
32 Muthusamy 37 100684
33 Basha 35 101108
34 Muthukumar 14 100800
35 Kumar 42 102500
36 Velmurugan 25 103640
37 Murugesan 40 105182
38 Prakash 36 106336
39 Jayaprakash 35 110726
40 Sivasubramaniyan 32 110734
S.NO Name AGE IP No
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
3 3 3.2 3.2 2 2
3 3.2 3.2 3.2 2.2 2
3 3 3.2 3.2 2 2
4 4 3.6 3.6 3 3
3 3.2 3.2 3.2 2 2
3.2 3.2 3.2 3 2.2 2.2
3 3 3 2.4 2.4 2
4.2 4.2 4 3.2 3.2 2.4
4.4 4 4 4 3.2 3
4.8 4.2 4 3.2 3 3
3 3.2 3.2 3.2 2 2
3.8 4 4 3.6 3 3
3 3 2.4 2.2 2.2 2
3 3 2.4 2 2 2
3.2 3.2 3 2.4 2.4 2
3.6 3.4 3.4 2 2 1.8
3.6 3.4 3.4 2 2 2
3.6 3 3 2.4 2.4 2
4.2 4 4 3.4 3 3
3 3 3 2 2 1.4
4.6 4 4 3 2.6 2
3 2.8 2.8 2 2 2
4 4 4 3 2.4 2
3.2 3 3 2.2 2.2 2
4.6 4 4.4 3.4 3 3
5.6 5.4
3 3 2.4 2 2 2
4.8 4.6 4.6 4 4 3.2
4.8 4.6 4.6 2 4 3.2
4.6 4.4 4.2 3.6 3.6 3
4.2 4 4 3.6 3 3
4 4 4 3.2 3 3
3 3 2.4 2 2 2
4 3.4 3.2 2.6 2 2
3 3 2.4 2 2 2
4 4 4 3.2 3 3
3.2 3 2.6 2.6 2 2
3 3 2.4 2.4 2 2
4.4 4.4 4 4 3.2 3
3 3 3 3 2 2
Alpha 1 Anti  Trypsin  (gm/Ltr)
S.NO Name AGE IP No
41 Arumugam 65 113706
42 Anandan 27 115890
43 Govindan 50 118184
44 Eswaran 40 23
45 Abinesh 24 828
46 Raja 40 386
47 Raju 40 40
48 Sudhakaran 50 4081
49 Madesh 35 6502
50 Selvakumar 40 7760
51 Yesudass 45 8642
52 Arjunan 27 1030
53 Thamaraikannan 27 9421
54 Shanmugam 43 11000
55 Rajivgandhi 32 12345
56 Murugan 50 14869
57 Murugesan 40 18034
58 Thangavel 60 22264
59 Raman 37 22300
60 Venkatesh 26 22579
61 Murugan 40 26890
62 Arumugam 36 26964
63 Vadivel 37 27048
64 Govindan 65 29541
65 Siva 30 29565
66 Kannan 31 30817
67 Arumugam 36 30990
68 Karupannan 65 34761
69 Tamilvannan 42 33581
70 Kuppusamy 45 34764
71 Dhamodharan 25 38129
72 Muthukaruppan 36 42136
73 Mani 40 32200
74 Vasanthakumar 45 34155
75 Senthil 32 391042
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
Alpha 1 Anti  Trypsin  (gm/Ltr)
3.6 3.6 3 3 2.3 2.2
4.4 4.4 4 3 3 2.4
3 3 3 2.4 2 2
3 3 2.6 2 2 2
3.4 3.3 3 2.2 2 2
4.6 4 4 4 3.4 3
4 4 4 3.6 3 2.6
3.6 3.4 3 3 2 2
3.6 3.4 3 3 2.2 2
3.2 2.8 2.2 1 1
4.6 4.2 4 4 3.6 3
4.6 4.4 4.4 4 3.2 3
4.8 4.6 4.6 4 3 3
3 3 2.6 2.6 2 2
4.6 4.6 4 4 3.6 3.5
3 3 3 2.6 2.2 2
3 3 3 2.4 2 2
3 3 3 2.4 2 2
4.2 4.2 4 4 3 3
3.2 3 3 2.6 2 2
4.8 4.6 4.6 4 3.5 3
3 3 3 2.4 2 2
3 3 3 3 2.5 2.5
4.4 4.4 4.2 3.6 1.6 1.2
4.1 4 4 3.5 3 3
3 3 2.7 2 2 1.2
4.4 4.2 4.2 4 3 3
4.6 4.4 4.4 3.5 3 3
4.4 4.2 4 3.2 3 2
4.8 4.4 4 3.8 3.2 2.5
4.4 4 4 3.6 3.2 3
4.8 4.6 4 4 3.5 3
4.4 4 4 3 2.8 2
4.8 4.8 4 4 3.2 3
3 3 2.5 2.4 2 1.6
1 Perumal 35 47048
2 Vijay 35 51792
3 Murugaiya 55 54678
4 Karthi 40 56582
5 Saravanan 30 58444
6 Iyappan 28 60936
7 Peraman 43 19115
8 Govindasamy 40 63640
9 Madesh 35 79736
10 Selvamani 56 81720
11 Madesh 38 84358
12 Thangaraj 45 85698
13 Selvaraj 50 36118
14 Parameshwaran 35 86030
15 Jeevasubramanian 42 86370
16 Nagaraj 28 87968
17 Ilayaraja 36 97934
18 Chandrasekaran 40 89344
19 Jayaraman 35 88222
20 Om prakash 29 39010
21 Peter 45 91358
22 Raja 23 94090
23 Manivel 30 96052
24 Raju 45 96158
25 Loganathan 43 97715
26 David 25 25347
27 Ramachandran 45 98320
28 Raja 45 99158
29 Arivalagan 44 99326
30 Sivasankar 19 100222
31 Ramesh 36 100308
32 Muthusamy 37 100684
33 Basha 35 101108
34 Muthukumar 14 100800
35 Kumar 42 102500
36 Velmurugan 25 103640
37 Murugesan 40 105182
38 Prakash 36 106336
39 Jayaprakash 35 110726
40 Sivasubramaniyan 32 110734
S.NO Name AGE IP No
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
58 60 54 40 24 10
55 65 58 32 12 8
42 40 44 30 10 6
98 190 172 140 100 60
40 68 52 33 18 10
52 76 68 38 18 8
54 96 100 84 42 12
102 132 121 100 92 68
99 142 104 98 83 75
158 170 132 84 86 58
52 48 32 20 14 8
106 174 153 92 69 40
38 40 34 22 16 8
44 63 52 40 22 6
50 42 32 26 14 6
42 68 50 34 18 8
40 52 38 23 18 10
38 46 30 25 16 8
120 152 138 82 60 52
46 64 50 34 20 6
110 176 142 98 64 38
50 64 44 30 22 10
118 142 102 94 78 60
63 74 48 23 11 6
84 113 90 63 40 22
164 192
38 58 40 36 24 8
114 134 120 94 78 60
126 132 102 90 71 62
78 82 64 48 30 21
138 150 120 89 62 48
144 164 140 109 84 30
44 30 24 14 10 6
122 144 120 99 77 48
50 56 42 28 16 8
100 142 138 109 74 42
62 70 44 28 18 10
60 68 42 30 18 6
78 94 84 69 55 30
38 40 30 18 10 6
C -Reactive Protein (mg/Ltr)
S.NO Name AGE IP No
41 Arumugam 65 113706
42 Anandan 27 115890
43 Govindan 50 118184
44 Eswaran 40 23
45 Abinesh 24 828
46 Raja 40 386
47 Raju 40 40
48 Sudhakaran 50 4081
49 Madesh 35 6502
50 Selvakumar 40 7760
51 Yesudass 45 8642
52 Arjunan 27 1030
53 Thamaraikannan 27 9421
54 Shanmugam 43 11000
55 Rajivgandhi 32 12345
56 Murugan 50 14869
57 Murugesan 40 18034
58 Thangavel 60 22264
59 Raman 37 22300
60 Venkatesh 26 22579
61 Murugan 40 26890
62 Arumugam 36 26964
63 Vadivel 37 27048
64 Govindan 65 29541
65 Siva 30 29565
66 Kannan 31 30817
67 Arumugam 36 30990
68 Karupannan 65 34761
69 Tamilvannan 42 33581
70 Kuppusamy 45 34764
71 Dhamodharan 25 38129
72 Muthukaruppan 36 42136
73 Mani 40 32200
74 Vasanthakumar 45 34155
75 Senthil 32 391042
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
C -Reactive Protein (mg/Ltr)
42 50 40 28 16 8
124 133 118 89 70 60
48 38 40 28 12 6
36 28 30 12 10 4
44 38 40 30 22 10
62 78 60 44 30 24
122 140 123 109 62 48
48 60 40 24 10 6
42 50 40 32 18 6
120 140 110 99 80 60
120 142 124 99 66 58
114 120 110 99 88 62
106 130 100 89 82 50
46 50 40 28 18 6
118 132 110 89 70 40
46 40 32 24 18 6
50 58 48 24 16 10
48 60 40 28 18 8
110 132 100 79 64 40
62 60 58 40 20 6
138 142 130 109 70 40
50 30 42 30 21 10
46 50 30 28 14 6
98 110 120 79 80 62
136 140 110 89 68 48
46 54 40 30 18 10
84 98 100 79 64 26
120 140 118 99 62 56
80 100 84 79 47 36
94 110 98 79 52 48
136 140 126 99 62 52
130 148 100 89 66 50
94 100 96 79 60 42
96 98 100 79 42 30
60 40 38 28 16 9
1 Perumal 35 47048
2 Vijay 35 51792
3 Murugaiya 55 54678
4 Karthi 40 56582
5 Saravanan 30 58444
6 Iyappan 28 60936
7 Peraman 43 19115
8 Govindasamy 40 63640
9 Madesh 35 79736
10 Selvamani 56 81720
11 Madesh 38 84358
12 Thangaraj 45 85698
13 Selvaraj 50 36118
14 Parameshwaran 35 86030
15 Jeevasubramanian 42 86370
16 Nagaraj 28 87968
17 Ilayaraja 36 97934
18 Chandrasekaran 40 89344
19 Jayaraman 35 88222
20 Om prakash 29 39010
21 Peter 45 91358
22 Raja 23 94090
23 Manivel 30 96052
24 Raju 45 96158
25 Loganathan 43 97715
26 David 25 25347
27 Ramachandran 45 98320
28 Raja 45 99158
29 Arivalagan 44 99326
30 Sivasankar 19 100222
31 Ramesh 36 100308
32 Muthusamy 37 100684
33 Basha 35 101108
34 Muthukumar 14 100800
35 Kumar 42 102500
36 Velmurugan 25 103640
37 Murugesan 40 105182
38 Prakash 36 106336
39 Jayaprakash 35 110726
40 Sivasubramaniyan 32 110734
S.NO Name AGE IP No
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
12000 12200 12200 11600 11400 11400
11000 11200 11200 10600 10400 10400
10800 10600 10600 9800 9600 9600
14200 14000 14000 13600 13400 13400
11000 11200 11200 10600 10200 10200
10800 10600 10600 10000 10200 10200
11000 11200 11200 10600 10400 10400
14600 14400 14400 14000 14000 13800
13600 13400 13400 12100 12000 12000
14300 14200 14200 13200 13000 13000
10000 10200 10200 9800 9600 9600
13000 12800 12800 12000 12000 12000
7800 8000 8000 7400 7500 7500
9600 9700 9700 10000 10200 10200
11000 11200 11200 12000 12100 12000
9800 9800 10000 11100 11200 11200
11000 11200 11200 12000 12200 12200
11000 11100 11100 12800 12800 12600
14400 14600 14600 12000 12000 12000
12000 12200 12200 11800 11600 11600
13600 13800 12600 12400 12400 12400
11000 11200 11200 10600 10400 10400
14600 14800 14800 13200 13000 13000
11000 11200 11200 10800 10600 10600
13800 14000 14000 13000 13000 13000
15400 15200
10200 10400 10400 9800 9600 9600
14800 14600 14600 12800 13000 13000
14600 14400 14400 13800 13600 13600
13800 13400 13600 12800 12600 12500
14000 14200 14200 13800 13600 13600
13600 13800 13800 12600 12400 12400
11000 10600 10600 9400 9600 9600
12800 12600 12600 11800 11600 11600
11400 11200 11200 10800 10800 10800
13200 13400 13400 12800 12600 12600
10400 10200 10200 9600 9800 9800
11200 11400 11400 10800 10600 10600
13200 13400 13400 12800 12400 12400
9800 9600 9600 8600 8400 8400
White cell count (Cells / Cu.mm)
S.NO Name AGE IP No
41 Arumugam 65 113706
42 Anandan 27 115890
43 Govindan 50 118184
44 Eswaran 40 23
45 Abinesh 24 828
46 Raja 40 386
47 Raju 40 40
48 Sudhakaran 50 4081
49 Madesh 35 6502
50 Selvakumar 40 7760
51 Yesudass 45 8642
52 Arjunan 27 1030
53 Thamaraikannan 27 9421
54 Shanmugam 43 11000
55 Rajivgandhi 32 12345
56 Murugan 50 14869
57 Murugesan 40 18034
58 Thangavel 60 22264
59 Raman 37 22300
60 Venkatesh 26 22579
61 Murugan 40 26890
62 Arumugam 36 26964
63 Vadivel 37 27048
64 Govindan 65 29541
65 Siva 30 29565
66 Kannan 31 30817
67 Arumugam 36 30990
68 Karupannan 65 34761
69 Tamilvannan 42 33581
70 Kuppusamy 45 34764
71 Dhamodharan 25 38129
72 Muthukaruppan 36 42136
73 Mani 40 32200
74 Vasanthakumar 45 34155
75 Senthil 32 391042
Da
y-
1
DA
Y-
3
DA
Y-
5
DA
Y-
7
DA
Y-
9
DA
Y-
11
White cell count (Cells / Cu.mm)
10600 10400 10400 9800 9600 9600
11400 11600 11600 10800 10600 10600
10400 10200 10200 9800 9600 9600
9800 9600 9600 8800 8600 8600
10200 10000 10000 9800 9600 9600
11200 11400 11400 10800 10600 10600
13200 13400 13400 13000 12800 12800
9600 9800 9600 9000 8800 8600
11000 11200 11200 10800 10800 10800
14900 14800 14800 13000 13200 13200
14600 14400 14400 13600 13000 13000
13600 13400 13400 12600 12800 12800
14200 14400 14400 13800 13600 13600
11000 11200 11200 11000 10800 10800
13600 13800 13800 12800 12600 12600
11000 11200 11200 10800 10600 10600
10800 10600 10600 10000 10200 10200
9800 9600 9600 9000 9200 9200
14200 14400 14400 13800 13600 13600
11800 11600 11600 10800 10600 10600
14200 14000 14000 13800 13600 13600
9800 9600 9600 8800 8600 8600
9600 9800 9800 8800 8600 8600
14600 14800 14800 13800 13600 13600
13800 13600 13600 13000 12800 12800
12000 12800 12800 11000 11200 11200
13800 13600 13600 13100 12900 12900
14200 14000 14000 13600 13800 13600
13800 13600 13600 12800 12600 12600
14400 14200 14300 13600 13400 13400
13600 13400 13400 12800 12600 12400
14000 14200 14200 13600 13400 13400
14300 14200 14200 13800 13600 13700
13600 13400 13300 13000 12600 12600
10000 10200 10200 9800 9600 9600
